Buchumschlag

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Giammarco Mocci, Antonio Tursi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
von: María Chaparro, et al.
Veröffentlicht: (2024)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
von: Shintaro Akiyama, et al.
Veröffentlicht: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety
von: Shintaro Sagami, et al.
Veröffentlicht: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
von: Remo Panaccione
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
von: L. A. A. P. Derikx, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis
von: Manuel Barreiro‐de Acosta, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
von: David Laharie
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
von: Matthias Lenfant, et al.
Veröffentlicht: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study
von: Merle Claßen, et al.
Veröffentlicht: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
von: Anthony Croft, et al.
Veröffentlicht: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
von: Vibeke Strande, et al.
Veröffentlicht: (2024)

Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people
von: Shuyao Song, et al.
Veröffentlicht: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
von: María Chaparro, et al.
Veröffentlicht: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question
von: Jenny Lövdahl, et al.
Veröffentlicht: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
von: Dipesh H. Vasant, et al.
Veröffentlicht: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
von: Fang Yan, et al.
Veröffentlicht: (2024)

Editorial: Do we Need to Adapt GERD Metrics Based on the Population Being Evaluated? Authors' Reply
von: Walter W. Chan, et al.
Veröffentlicht: (2026)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
von: David Bergman, et al.
Veröffentlicht: (2024)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
von: Maryam Alahmad, et al.
Veröffentlicht: (2024)

Editorial: Is TIPSS Implantation Effective in Patients With Portal Hypertensive Gastropathy?
von: Marlene Reincke, et al.
Veröffentlicht: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests?
von: C. Gaume, et al.
Veröffentlicht: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
von: Maria Gabriela Fernandes Dezan, et al.
Veröffentlicht: (2024)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
von: C. Ramos‐Belinchon, et al.
Veröffentlicht: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
von: Mark A. Ainsworth, et al.
Veröffentlicht: (2025)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
von: Olga P. Nyssen, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
von: Nicolas Richard, et al.
Veröffentlicht: (2025)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
von: Jakob B. Seidelin
Veröffentlicht: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
von: Shinichiro Shinzaki, et al.
Veröffentlicht: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
von: Simone Chin, et al.
Veröffentlicht: (2025)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
von: Gustavo Ayares, et al.
Veröffentlicht: (2024)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
von: Marco Vincenzo Lenti, et al.
Veröffentlicht: (2025)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
von: Guilherme Grossi Lopes Cançado
Veröffentlicht: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
von: C. M. Fernández‐Rodríguez, et al.
Veröffentlicht: (2024)

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
von: Stefan Schreiber, et al.
Veröffentlicht: (2024)